180 related articles for article (PubMed ID: 34389223)
1. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib.
Holowka T; Cheung H; Malinis M; Gan G; Deng Y; Perreault S; Isufi I; Azar MM
J Infect Chemother; 2021 Dec; 27(12):1700-1705. PubMed ID: 34389223
[TBL] [Abstract][Full Text] [Related]
2. Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration.
Walker C; Horowitz A; Nooruddin Z; Frei CR
J Oncol Pharm Pract; 2024 Jun; 30(4):673-677. PubMed ID: 37309168
[TBL] [Abstract][Full Text] [Related]
3. Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies.
Tham K; Prelewicz S; deHoll S; Stephens DM; Gomez CA
Am J Health Syst Pharm; 2024 Feb; 81(4):112-119. PubMed ID: 37675967
[TBL] [Abstract][Full Text] [Related]
4. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study.
Allouchery M; Brunet K; Tomowiak C; Singier A; Pambrun E; Pariente A; Bezin J; Pérault-Pochat MC; Salvo F
Mycoses; 2024 Jan; 67(1):e13676. PubMed ID: 37984556
[TBL] [Abstract][Full Text] [Related]
5. Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.
Egger M; Gornicec M; Wölfler A; Lembeck AL; Tinchon C; Maderdonner M; Prattes J
Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36029283
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R
Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465
[TBL] [Abstract][Full Text] [Related]
7. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
Varughese T; Taur Y; Cohen N; Palomba ML; Seo SK; Hohl TM; Redelman-Sidi G
Clin Infect Dis; 2018 Aug; 67(5):687-692. PubMed ID: 29509845
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.
Gold JAW; Tolu SS; Chiller T; Benedict K; Jackson BR
Clin Infect Dis; 2022 Aug; 75(2):334-337. PubMed ID: 34893821
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Brochard J; Morio F; Mahe J; Le Pape P; Guimard T; Mahe B; Leterrier M; Morrier M; Raffi F; Boutoille D
Med Mal Infect; 2020 Nov; 50(8):742-745. PubMed ID: 32777360
[TBL] [Abstract][Full Text] [Related]
10. [Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia].
Kumekawa H; Watanabe D; Tamura K; Mizuchi D
Rinsho Ketsueki; 2022; 63(1):62-65. PubMed ID: 35135954
[TBL] [Abstract][Full Text] [Related]
11. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
[TBL] [Abstract][Full Text] [Related]
13. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
Front Immunol; 2020; 11():2158. PubMed ID: 32983178
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Ruchlemer R; Ben-Ami R; Bar-Meir M; Brown JR; Malphettes M; Mous R; Tonino SH; Soussain C; Barzic N; Messina JA; Jain P; Cohen R; Hill B; Mulligan SP; Nijland M; Herishanu Y; Benjamini O; Tadmor T; Okamoto K; Arthurs B; Gottesman B; Kater AP; Talha M; Eichhorst B; Korem M; Bogot N; De Boer F; Rowe JM; Lachish T
Mycoses; 2019 Dec; 62(12):1140-1147. PubMed ID: 31520441
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008-2013.
Chen CY; Sheng WH; Tien FM; Lee PC; Huang SY; Tang JL; Tsay W; Tien HF; Hsueh PR
J Microbiol Immunol Infect; 2020 Feb; 53(1):106-114. PubMed ID: 29449166
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation.
Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Chen PM; Tzeng CH
J Microbiol Immunol Infect; 2016 Aug; 49(4):567-74. PubMed ID: 25735797
[TBL] [Abstract][Full Text] [Related]
17. Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study.
Baucher L; Lemiale V; Joseph A; Wallet F; Pineton de Chambrun M; Ferré A; Lombardi R; Platon L; Contejean A; Fuseau C; Calvet L; Pène F; Kouatchet A; Mokart D; Azoulay E; Lafarge A
Ann Intensive Care; 2023 Dec; 13(1):123. PubMed ID: 38055081
[TBL] [Abstract][Full Text] [Related]
18. Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Ball S; Das A; Vutthikraivit W; Edwards PJ; Hardwicke F; Short NJ; Borthakur G; Maiti A
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):87-97.e5. PubMed ID: 31787589
[TBL] [Abstract][Full Text] [Related]
19. Invasive fungal infections associated with prior respiratory viral infections in immunocompromised hosts.
Ajmal S; Mahmood M; Abu Saleh O; Larson J; Sohail MR
Infection; 2018 Aug; 46(4):555-558. PubMed ID: 29627936
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
DiSogra KY; Tran T; Arnall JR; Janes A; Moore DC; Park SI
J Oncol Pharm Pract; 2021 Jul; 27(5):1265-1269. PubMed ID: 33106104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
